Psychiatry related information on Paraphilias

• CONCLUSION: Although depressive disorders were the most common Axis I diagnoses across groups, childhood ADHD was the only Axis I disorder statistically significantly associated with paraphilias, socially deviant and aggressive forms of sexual impulsivity [1].
• Other paraphilias have been attributed to dopamine agonists, suggesting that the action of the monoamine oxidase inhibitor responsible for the patient's transvestism in this case was dopamine potentiation [2].

High impact information on Paraphilias

• Treatment of paraphilia with an analogue of gonadotropin-releasing hormone [3].
• To examine the possible effect of progesterone on circulating T4-binding globulin (TBG) in men, RIA measurements of plasma TBG and T4 levels were made before and after weekly administration of 500 mg medroxyprogesterone acetate, im, to men being treated for paraphilia (sexual deviation syndromes) [4].
• Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series [5].
• BACKGROUND: We describe an open trial of psychostimulants (primarily methylphenidate sustained release [SR]) added to selective serotonin reuptake inhibitors (SSRIs; primarily fluoxetine) during the course of pharmacologic treatment of men with paraphilias and paraphilia-related disorders (PRDs) [5].
• CONCLUSION: Methylphenidate SR can be cautiously and effectively combined with SSRI antidepressants to ameliorate paraphilias and paraphilia-related disorders for the indications listed above [5].

Chemical compound and disease context of Paraphilias

• Paraphilias, impulse control, and serotonin [6].
• Three cases of paraphilias responsive to fluoxetine treatment [7].
• Low-dose oral medroxyprogesterone acetate in the management of the paraphilias [8].
• Nine of 10 consecutively evaluated men with DSM-III-R nonparaphilic sexual addictions or paraphilias noted improvement in sexual behaviors and depressive symptomatology while treated with fluoxetine, imipramine, or lithium [9].
• High-dose depot MPA treatment (500-800 mg i.m. weekly) has proven to control the behavioral manifestations of the paraphilias when testosterone levels decrease from pretreatment to prepubescent levels, but at the price of significant morbidity [8].

Biological context of Paraphilias

• This paper considers human sexual orientation, specifically homosexuality and some paraphilias, to occur as a result of intrauterine development, itself a mathematically chaotic process [10].

Gene context of Paraphilias

• BACKGROUND: We describe a study of DSM-III-R Axis I diagnoses of lifetime comorbid nonsexual disorders in 60 males with paraphilias (PAs; N = 42) and nonparaphilic forms of sexual impulsivity-designated paraphilia-related disorders (PRD; N = 18) [1].
• Obsessive-compulsive disorder and paraphilia in a monozygotic twin pair [11].
• The management of a case of treatment-resistant paraphilia with a long-acting LHRH agonist [12].
• Findings support the hypotheses that sexual disorders are frequent among HD patients and their partners and that sexual disorders among HD patients may take the form of increased sexual interest or paraphilias [13].
• It is argued that the same criteria that led to the removal of homosexuality per se as a mental disorder require the removal of all the paraphilias per se, there is no empirical warrant to justify their continued inclusion, and while there is legitimacy for a generalized ego-dystonic category, such ego-dystonias are only incidentally sexual [14].

Analytical, diagnostic and therapeutic context of Paraphilias

• Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists [15].
• Osteoporosis and long-term androgen suppression in the treatment of paraphilias has been documented with surgical castration and the use of gonadotropin-releasing hormone agonists [16].

References